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Polycomb group (PcG) proteins act as positive regulators of cell proliferation. Ring1B is a PcG gene essential
for embryonic development, but its contribution to cell turnover in regenerating tissues in not known. Here, we
have generated a conditional mouse mutant line to study the Ring1B role in adult hematopoiesis. Mutant mice
developed a hypocellular bone marrow that paradoxically contained an enlarged, hyperproliferating compart-
ment of immature cells, with an intact differentiation potential. These alterations were associated with
differential upregulation of cyclin D2, which occurred in all mutant bone marrow cells, and of p16Ink4a,
observed only in the differentiated compartment. Concurrent inactivation of Ink4a rescued the defective
proliferation of maturing cells but did not affect the hyperproliferative activity of progenitors and resulted in
a shortening of the onset of lymphomas induced by Ink4a inactivation. These data show that Ring1B restricts
the progenitors’ proliferation and promotes the proliferation of their maturing progeny by selectively altering
the expression pattern of cell cycle regulators along hematopoietic differentiation. The novel antiproliferative
role of Ring1B’s downregulation of a cell cycle activator may play an important role in the tight control of
hematopoietic cell turnover.
Adult multicellular organisms have evolved cell turnover
strategies adapted to the maintenance and repair of tissues. In
many cases, such as the hematopoietic system, gut, skin, and
brain, tissue homeostasis depends on the activity of multipo-
tent stem cells from which derive all the cell lineages that make
these tissues (17, 56). Because of the relatively small number of
stem cells, their progeny undergoes an expanding but limited
number of cell divisions along the differentiation process be-
fore entering the mitotically inactive state of fully mature cells.
Tissue homeostasis, then, depends on an adequate balance
between stem cell renewal, regulated cell proliferation, and
terminal differentiation of stem cell progeny (58, 74).
The Polycomb group (PcG) of proteins are transcriptional
repressors that prevent the inappropriate expression of genes
that determine cell identity (4, 11). PcG gene products assem-
ble in multimeric complexes (Polycomb repressing complexes
[PRC]) whose transcriptional activity is associated to their role
as chromatin modifiers (64). PRC are compositionally diverse,
but depending on which of two sets of core subunits they
contain, they are designated type PRC1 or PRC2 (40). Histone
H2AK119 monoubiquitylation depends on the RING finger
E3 ligases of PRC1 complexes (10, 73), whereas histone
H3K27 trimethylation is carried out by PRC2 complexes (12,
18, 34, 46). Well known as developmental regulators (57), PcG
genes also play important roles in cell proliferation control (41,
52). Murine models of loss of function of PcG genes encoding
PRC1 subunits show reduced size and hypocellularity of he-
matopoietic organs (1, 15, 69, 70) and also, in some cases
(Bmi1) of brain structures (71), indicating that PcG complexes
are positive regulators of cell proliferation. The upregulation
of PcG products observed in a wide variety of tumors (54, 68)
and their cooperation in oncogene-induced tumorigenesis (27)
further support a role for PcG complexes as promoters of
proliferation. Exceptionally, inactivation of the PRC2 subunit
Eed resulted in enlarged hematopoietic compartments (36).
These alterations are due, at least in part, to PcG-mediated
repression of the Ink4a/Cdkn2a locus, which encodes the tu-
mor suppressors p16Ink4a and p19Arf. Loss of function of PRC1
proteins, and Bmi1 in particular, results in premature senes-
cence of hematopoietic and neuronal stem cells (28, 37, 44, 48,
49, 51). PcG complexes also promote expansion of maturing
cells by preventing senescence and apoptosis, although the
contribution of each of these mechanisms varies depending on
the particular tissue and the PcG protein (9, 14, 38, 45).
Ring1B and its paralog Ring1A are the RING finger E3
ligases that monoubiquitylate H2A (20, 73). They associate
directly with Bmi1, Mel18, M33, and Phc1, forming the core of
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PRC1 complex(es) (25, 39, 63). The contribution of Ring1A
and Ring1B to cell turnover of renewing tissues is not known.
Constitutive inactivation of Ring1A results in fertile mice with
no overt phenotypes (19), whereas inactivation of Ring1B
leads to embryonic lethality due to defective gastrulation (72).
Considering that Ring1B expression in the adult hematopoi-
etic compartment is detected in all differentiation stages, from
the hematopoietic stem cells (HSCs) and their immature de-
scendants (29), we sought to address the role of Ring1B in
adult hematopoiesis using a conditional mutant mouse line.
We find that Ring1B inactivation results in a reduction of total
bone marrow cells and, at the same time, an enlargement of
the immature cell compartment. We also show that the alter-
ations in the size of bone marrow cell populations are due to
cell proliferation defects caused by upregulation of compo-
nents of the cell cycle machinery that act as activators (cyclin
D2) or inhibitors (p16Ink4a) of proliferation in a differentiation
stage-dependent manner. Finally, we observed premature de-
velopment of lymphomas in compound Ring1B;Ink4a mutant
mice that suggests an important role for Ring1B in controlling
the expansion of progenitor cells in adult hematopoiesis.
MATERIALS AND METHODS
Mice, genotyping, and conditional inactivation of Ring1B. Ring1B genomic
sequences for the targeting vector were generated from a partial genomic clone
isolated from a mouse 129SVJ Lambda FIX II phage library (Stratagene) probed
with a Ring1B cDNA. The 5 arm of the targeting vector was a 4,680-kb EcoRI-
BstNI fragment corresponding to sequences located 4,464 bp 5 from the intron
2-exon 3 junction, and the 3 arm was a 5,286-bp BstNI-EcoRI fragment encom-
passing sequences up to 97 bp 3 of the exon 5-intron 5 boundary. They were
subcloned into pPGKneo2loxDTA plasmid (67), which contains a phosphoglyc-
erol kinase promoter-neomycin resistance gene cassette flanked by two loxP sites
and a phosphoglycerol kinase-diphteria toxin gene cassette (see Fig. S1A in the
supplemental material). The 5 arm was modified by inserting an oligonucleotide
containing a loxP sequence and a BglII site at the AvrII site 197 bp 5 from the
intron 1-exon 2 junction using a PCR strategy. The targeting construct was
linearized and electroporated into 2  107 mouse R1 embryonic stem (ES) cells.
Colonies surviving the G418 selection were transferred into duplicated 48-well
plates, which were used to prepare frozen stocks of the ES cell colonies and to
isolate genomic DNA, respectively. The targeted allele was identified by South-
ern blotting using probes external to the targeting vector (see Fig. S1A in the
supplemental material). Two Ring1Bflox/ (hereafter, Ring1Bf/) ES clones were
aggregated with morulae obtained from C57Bl10 mice, and the resulting chi-
meric males were mated to C57Bl10 mice, and heterozygous animals were iden-
tified by Southern blotting. For routine genotyping, genomic DNA was analyzed
by using a three-primer PCR (see Fig. S1A in the supplemental material).
For in vivo conditional inactivation, Ring1Bflox/flox (hereafter, Ring1Bf/f) mice
were crossed with MxCre transgenic mice (33). MxCre expression was induced by
intraperitoneally injecting 250 g of polyinosine-polycytidine (pIpC; Pharmacia)
on three alternate days in 6- to 12-week-old mice. “Ex vivo” conditional inacti-
vation of Ring1B was carried out on cells obtained from mice generated by
crossing Ring1Bf/f mice with RERTert mice, a mouse line in which an IRES-Cre-
ERT2 (tamoxifen-inducible Cre) cassette was knocked in into the 3 untranslated
region of the RNA polII (Polr2a) gene (43), to obtain Ring1Bf/f; RERTert/ert mice
(here termed Ring1Bf/f CreERT2). Translocation of Cre-ERT2 to cell nuclei and
loxP recombination were achieved by adding to the cultures 4-hydroxy tamoxifen
([4-HT] 0.4 M final concentration; Sigma) or vehicle (4-HT and 4-HT
cultures, respectively).
Compound Ring1Bfl/fl; Ink4a/ mice were obtained by crossing Ring1Bf/f mice
with the Ink4a/ mouse line (65). Genotyping of the Ink4a allele was done by
Southern blotting as described previously (65). All mouse procedures were in-
stitutionally approved and were in accordance with national and European reg-
ulations.
Cell counting and blood analysis. Bone marrow cells were flushed out of both
femurs with phosphate-buffered saline (PBS) containing 2% fetal calf serum
(PBS–2% FCS) under sterile conditions. Spleens and thymi were disrupted in a
Dounce homogenizer (loose pestle) in PBS–2% FCS. Cells were counted in a
hemocytometer.
Blood was obtained by heart puncture immediately after mice were sacrificed.
Blood counts were mostly performed by manual counting on a hemocytometer or
automatically using an Abacus (Diatron) hematological analyzer. Manual count-
ing of white blood cells was carried out after erythrocytic lysis.
Immunophenotyping and cell separation. Single-cell suspensions were washed
with PBS and resuspended in cold washing solution (PBS–2% FCS–0.1% sodium
azide). The appropriate antibodies were then added, and cells were labeled for
20 min at 4°C. After a washing step, cells labeled with biotin-conjugated anti-
bodies were further incubated with streptavidin conjugated to phycoerythrin
(PE) or peridinin chlorophyll protein-Cy5.5. Samples were acquired in a FAC-
Scan fluorescence-activated cell sorter (FACS) instrument with CellQuest soft-
ware or a FACSCanto with Diva software, all from Becton Dickinson. The
antibodies that were used were as follows: c-Kit conjugated to fluorescein iso-
thiocyanate (FITC), biotin, or allophycocyanin (for analysis); Sca-1, Gr-1, CD41,
and B220 conjugated to FITC or biotin; Mac-1, CD3, and Ter119 conjugated to
biotin; CD34 conjugated to FITC; FcR and CD19 conjugated to PE. All anti-
bodies were purchased from BD Biosciences.
For common myeloid progenitor (CMP) sorting, isolated colonies with imma-
ture phenotype were pooled, immunomagnetically depleted of Lin cells, and
labeled with anti-c-Kit-allophycocyanin -, anti-CD34-FITC-, and anti-FcR-PE-
conjugated antibodies and sorted on the c-Kit/CD34/FcRlo gate in a FACS
Vantage sorter equipped with a Diva system (BD Biosciences), set to render the
highest purity. Immunomagnetic cell isolation was done using a Lineage Cell
Depletion kit and LD columns together with a QuadroMACS separation unit
from Miltenyi Biotec. Hematopoietic cell subpopulations for Ring1B expression
analysis were isolated by cell sorting as described previously (30), using Mac1
Gr1lo for monocytic and Mac1 Gr1high for granulocytic precursors, respectively,
in a FACS Vantage sorter (BD Biosciences).
In vitro colony forming assays. Myeloid and pre-B-cell colony plating assays
were performed in cytokine-supplemented methylcellulose-based medium
M3434 and M3630 (StemCell Technologies), seeding total bone marrow in
duplicate (2  105 or 2  104 cells/35-mm dish for pre-B-cell and myeloid assays,
respectively). For assays of isolated progenitors, 500 Lin cells were used per
plate. Myeloid cultures were scored for colony formation and morphologically
analyzed at day12 unless otherwise specified. Pre-B-cell and immature myeloid
colonies were systematically scored at day 8 and day 7 after seeding, respec-
tively. Serial replating, using equal numbers of cells, was performed 10 days after
plating.
Cell proliferation, cell division, and apoptosis assays. Bone marrow or iso-
lated Lin cells were cultured in 24-well plates containing Iscove’s modified
Dulbecco’s medium–10% FCS medium plus 20 or 50 ng/ml of recombinant
murine interleukin-3 (IL-3) or recombinant human IL-6, respectively (Pepro-
tech). Recombination in cultured cells was achieved by adding 4-HT (0.4 M;
Sigma) or vehicle, where indicated. Lin cells cultures also contained 100 ng/ml
of recombinant human stem cell factor (Peprotech). Viable cells were counted by
trypan blue exclusion in a hemocytometer.
Bromodeoxyuridine (BrdU) incorporation was assessed by adding the nucle-
otide precursor analog to the culture medium at a final concentration of 10 M.
After 18 h labeled cells were determined with a flluorochrome-conjugated anti-
BrdU antibody (FITC BrdU flow kit; BD-Pharmingen) and analyzed by flow
cytometry in a FACScan cytometer equipped with CellQuest software (BD
Biosciences). For cell division assays, cells were labeled with 2 M carboxy-
fluorescein diacetate succinimidyl ester (CFDA-SE) and handled as indicated by
the manufacturer (Invitrogen). Cell-associated fluorescence was analyzed by flow
cytometry 18 h later. To determine the fluorescence associated to cells before
division, two aliquots were removed: one was analyzed immediately, and the
second was kept at 4°C to match the analysis conditions. An FITC-conjugated
recombinant human annexin V kit (Bender Medsystems) was used to stain
apoptotic cells prior to flow cytometry analysis.
Western blotting analysis. Cells were lysed in radioimmunoprecipitation assay
buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% TX-100, 0.1% sodium
dodecyl sulfate, 1% deoxycholate, 5 mM EDTA, 20 mM NaF, 100 M or-
thovanadate, and protease inhibitors) for 30 min on ice. Cell lysates were cleared
of debris by centrifugation at 15,000  g for 15 min, aliquoted, snap-frozen, and
kept at 70°C until used. Thirty micrograms of total protein was subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to
BioTrace polyvinylidene difluoride membranes (Pall Corporation) for 1 h at 2
mA/cm2 on a semidry transfer apparatus (Amersham). Ponceau staining was
routinely performed on membranes, and digital photographs were taken in order
to record a sample loading control. After being blocked in Tris-buffered saline
containing 0.1% Tween 20 and 5% nonfat dry milk, filters were incubated
VOL. 28, 2008 Ring1B CONTROL OF CELL PROLIFERATION 1019
overnight at 4°C with the following antibodies: anti-Ring1B (63), anti-p16Ink4a
(M-156; Santa Cruz), anti-cyclin D2 (M-20; Santa Cruz), anti-cyclin D3 (C-16;
Santa Cruz), anti-p27kip1 (clone 57; Transduction Laboratories), anti-cdc6 (Ab-3;
Oncogene), anti-p57kip2 (KP-39; Sigma), anti-cyclin A (H-432; Santa Cruz), anti
p19Arf (ab80; Abcam). After a washing step and incubation with horseradish
peroxidase-conjugated secondary antibodies (Dako), signals were detected using
an enhanced chemiluminescence system (Pierce).
Histopathology and immunohistochemistry. Normal and tumor tissue samples
were fixed in 10% neutral-buffered formalin for 24 h. After dehydration and
paraffin wax embedding, 3-m sections were prepared and stained with hema-
toxylin and eosin. For immunohistochemical analysis, sections were mounted on
poly-L-lysine-coated slides, and anti-Pax5 antibodies were detected by the avidin-
biotin-peroxidase complex method (Peroxidase Elite, Vectastain, and ABC kit;
Vector Laboratories).
Quantitative reverse transcription-PCR expression analysis. RNA was iso-
lated from sorted hematopoietic cell populations using an RNeasy kit (Qiagen).
Random-primed cDNA was generated using a Superscript III First Strand re-
verse transcription kit (Invitrogen). Triplicate reactions of cDNA amplification
were performed in Sybr Premix Ex Taq (Takara) and analyzed using a 7900HT
Fast Real-Time PCR System (Applied Biosystems). Relative mRNA normalized
to acidic ribosomal phosphoprotein mRNA levels was determined using the
comparative cycle threshold (CT) method. The following sets of primers were
used: for Ring1B, TTGACATAGAATGGGACAGC (forward) and GTCAGC
AGAAAGTCTTGTGG (reverse); for acidic ribosomal phosphoprotein, CGAC
CTGGAAGTCCAACTAC (forward) and ATCTGCTGCATCTGCTTG (re-
verse).
ChIP. Lin and Lin bone marrow cells were processed for chromatin im-
munoprecipitation (ChIP) assays using anti-trimethylated H3K27 (Upstate),
anti-Ring1B (3), and anti-Bmi1 (21) antibodies. Immunoprecipitated DNA was
amplified using the primer pair TTGCCCTGAATATAGCATGA and TCATG
CTATATTCAGGGCAA or the pair CGATCCTTTAGCGCTGTTTC and CA
CACTCTGCTCCTGACCTG that span 271 bp and 201 bp in the murine
p16Ink4a gene promoter area, respectively.
Statistical analyses. Values are expressed as means  standard deviation
(SD). Data sets were compared using a two-tailed Student’s t test, and differences
were considered significant for P values of 	0.05.
RESULTS
Loss of Ring1B leads to concurrent bone marrow hypocel-
lularity and enlarged immature cell compartments. Ring1B
mRNA expression was found to be ubiquitous in hematopoi-
etic cells, from the most primitive HSC and its derived pro-
genitors (CMP and common lymphoid progenitor) through
more committed but still immature bivalent progenitors
(granulo-monocytic progenitors [GMPs] and megakaryo-
erythrocytic progenitors [MEP]) and the most mature myeloid
and lymphoid cells (Fig. 1A). To study the function of Ring1B
during adult hematopoiesis, we crossed a pIpC-inducible
MxCre mouse line that expresses the Cre recombinase in the
hematopoietic compartment (33) with a conditional Ring1Bf/f
mouse line (Fig. 1B) to produce Ring1Bf/f; MxCre mice and
their MxCre-negative littermate controls. Six- to 12-week-old
mice were treated with pIpC and sacrificed 4 weeks later. The
treatment resulted in efficient deletion of alleles flanked by
loxP sites (see Fig. S1A in the supplemental material) and loss
of Ring1B protein in the bone marrow (Fig. 1B).
Examination of circulating blood cells and secondary hema-
topoietic organs (spleen and thymus) of MxCre-positive and
MxCre-negative mice showed only mild, but consistent, reduc-
tion of erythrocytes and splenocytes in most mutant animals
and a few thrombocytotic individuals (see Fig. S2A and B in
the supplemental material). Immunophenotypic analysis of
bone marrow cells showed no remarkable differences in lin-
eage composition between normal and mutant mice, except for
a slight decrease of mutant lymphoid B cells (see Fig. S2C in
the supplemental material). A relevant difference, however,
was seen in total bone marrow cell numbers, which were re-
duced upon Ring1B ablation by nearly one-third (P 
 0.001)
(Fig. 1C). In contrast, the progenitor compartment (minority
cells lacking lineage differentiation markers, i.e., Lin cells)
was enlarged in mutant bone marrow (Fig. 1D). The HSC-
enriched subpopulation (Lin cells that simultaneously express
c-Kit and Sca-1 markers) was also larger than that of Ring1B-
expressing cells (Fig. 1E). Thus, Ring1B ablation resulted in
concurrent hypocellularity of the mature bone marrow and an
increased number of progenitor cells, with no apparent alter-
ations in lineage specification.
Cell-autonomous increase of Ring1B-deficient myeloid clo-
nogenic cells. Clonogenic assays were employed to determine
FIG. 1. Conditional targeting of Ring1B and analysis of Ring1B-
deficient bone marrow cells. (A) Analysis by quantitative reverse tran-
scription-PCR of the expression levels of Ring1B in the indicated
subpopulations of hematopoietic progenitors and their maturing prog-
eny. LSK, LinSca-1c-Kit cells, corresponding to long- and short-
term HSCs; CLP, common lymphoid progenitors; Mac1, monocytic
precursors; Gr1, granulocytic precursors; CD19, B-cell precursors;
Ter119, erythocytic precursors. Each value has been normalized for
acidic ribosomal phosphoprotein expression levels. (B) Schematic rep-
resentation of strategy used to ablate Ring1B in vivo and results of
Ring1B detection by Western blotting in bone marrow from Ring1Bf/f
mice and from mice lacking the Ring1B locus (Ring1B/). (C) Total
bone marrow cell count from Ring1Bf/f (n 
 20; Cre) and Ring1B/
(n 
 20; Cre) mice. (D) Absolute (top) and relative (bottom) num-
bers of bone marrow cells lacking lineage markers (Lin population,
corresponding to HSC and all progenitor cells) from Ring1Bf/f (n 
 12;
Cre) and Ring1B/ (n 
 12; Cre) mice. (E) Absolute (top) and
relative (bottom) numbers of LSK population (corresponding to long-
and short-term HSCs) from control (n 
 10; Cre) and mutant (n 

10; Cre) immunomagnetically isolated Lin cells. BM, bone marrow;
IFN-, gamma interferon; wt, wild type; Tg, transgenic.
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the abundance of cells (CFU) able to expand and give rise to
differentiated progeny in vitro. These include primitive, mul-
tilineage progenitors and immediate unilineage precursors that
give rise to characteristic, morphologically distinguishable col-
onies. For lymphoid cells, clonogenic assays in the presence of
IL-7 revealed a severe reduction in the number and size of
Ring1B-deficient pre-B-cell colonies (Fig. 2A). On the other
hand, ablation of Ring1B resulted in an almost twofold increase
of myeloid CFU (Fig. 2B). Whereas all types of supported
CFU were represented, their relative proportions were altered,
particularly the mixed granulo-mono-erythromegakaryocitic
(GEMM) colonies (sixfold increase; P 	 0.0001) (Fig. 2B)
originated from the most immature progenitors. The GEMM
colonies derived from blast-like cell clusters, which in mutant
bone marrow cultures appeared invariably denser (Fig. 2C,
top) and also contained a higher proportion of the primitive
CMP (fivefold increase; P 
 0.05) (Fig. 2C, bottom). We con-
clude that Ring1B clearly affected both the size and clonogenic
activity of the progenitors’ compartment.
Since extrinsic signals affect hematopoiesis, we aimed to
determine the cell-autonomous contribution to the above al-
terations. To do this, we devised an ex vivo Ring1B inactivation
system that used bone marrow cells from Ring1Bf/f; Cre-ERT2
mice. These were obtained by crossing the conditional
Ring1Bf/f mouse line with a RERTert mouse deleter line
(Cre-ERT2::Polr2a [43]) (see Fig. S3A in the supplemental
material). The mouse deleter line ubiquitously expresses a
tamoxifen (4-HT)-inducible fusion protein between the Cre
recombinase and a mutated ligand binding domain of the hu-
man estrogen receptor. Bone marrow cells from these mice
were cultured in parallel in the absence (Cre) and in the
presence (Cre) of 4-HT to generate control and Ring1B-
deleted cells, respectively. Efficient Ring1B ablation was
achieved 2 days after 4-HT treatment (see Fig. S3B in the
supplemental material). As seen above for in vivo Ring1B-
inactivated bone marrow cells (Fig. 2A and B), 4-HT treatment
resulted in a reduction of pre-B-cell colonies, an increase in
total Lin cells, and a larger number of myeloid CFU (see Fig.
S3C to E in the supplemental material). Consistent with this,
mutant progenitors (4-HT; Cre) yielded more secondary
and tertiary colonies in a replicating assay than control pro-
genitors (4-HT; Cre), indicating a higher self-renewal rate
of Ring1B-deficient cells (Fig. 2D). These results indicate that
alteration of immature cell populations and of their clonogenic
activities are mostly due to a cell-autonomous defect resulting
from the ablation of Ring1B.
Ring1B inactivation enhances the proliferative rate of my-
eloid progenitors. We used ex vivo inactivation of Ring1B to
investigate whether differences in cell proliferation rate, apop-
tosis, or cell differentiation could account for the accumulation
of Ring1B-deficient primitive hematopoietic cells. Pulse label-
ing of Lin cells with BrdU demonstrated that more cells
incorporated BrdU in 4-HT-treated (Cre) than in nontreated
(Cre) cultures (Fig. 3A). We also used CFDA-SE fluores-
cence decay as an additional test of the cell division rate. This
assay is based on the dilution of the fluorescent dye resulting
from its equal distribution among daughter cells upon cell
division. As shown in Fig. 3B, nearly all Ring1B-deficient Lin
cells had completed one cell cycle at the same point when 30%
of the Ring1B-expressing Lin cells still remained undivided.
Under these culture conditions, annexin V labeling (an indi-
cator of apoptosis) showed no differences between treated and
nontreated cultures (Fig. 3C). These results indicate that the
enlargement of the mutant Lin compartment is due to an
increase in the cell proliferation rate provoked by the loss of
Ring1B.
Although the representation of the various lineages in bone
marrow and circulating cells in Ring1B mutant mice suggested
that no major alterations in differentiation were occurring, we
further tested this by immunophenotyping cells generated in
methylcellulose cultures of Lin cells. As seen in Fig. 3D,
levels of Gr-1, Mac-1, and CD-41 lineage markers (specific for
granulocytes, monocytes, and megakaryocytes, respectively)
showed no differences between cultures from Ring1B-deleted
and nondeleted Lin cells. Moreover, FACS-sorted mutant
CMPs retained the ability to give rise in vitro to more mature
progeny, MEPs and GMPs (Fig. 3E). Together, these data
FIG. 2. Clonogenic assays of Ring1B-deficient bone marrow cells.
(A) Impaired pre-B-cell colony formation in mice in which the Ring1B
locus has been excised as a result of the expression of MxCre. Colonies
generated per 5  105 bone marrow cells from mutant (n 
 14; Cre)
and control (n 
 12; Cre) mice. At right are images of representative
colonies at day 8 of culture. (B) Increased myeloid clonogenic activ-
ity in MxCre (excised Ring1B) mice (n 
 14; Cre) compared to
MxCre (nonexcised Ring1B) mice (n 
 16; Cre). Bar segments
represent the average absolute number (CFU) of the various colony
types: unilineage monocytic (M), granulocytic(G), and erythrocytic
(BFU-E) and bilineage granulo-monocytic (GM) and GEMM (mixed)
colonies. (C) Myeloid colonies. At top are photographs of represen-
tative individual immature colonies picked at day 7 of culture; at
bottom are contour plots of the flow cytometry analysis of these col-
onies showing the myeloid progenitors MEPs, GMPs, and CMPs iden-
tified as CD34 FcRlo (lower left lobe), CD34 FcR (upper right
lobe), and CD34 FcRlo (lower right lobe; almost absent in control
Cre colonies), respectively. A representative experiment (out of
three) is shown, indicating the CMP relative content value  SD.
(D) Replicating assay of ex vivo Ring1B-excised bone marrow cells.
The results are shown as the mean  SD (n 
 6) of the total number
of secondary and tertiary colonies generated from identical numbers of
pooled primary control (4-HT) and mutant (4-HT) myeloid colo-
nies.
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strongly suggest that the accumulation of early progenitor cells
resulting from Ring1B inactivation is mostly due to an en-
hanced proliferation rate of myeloid progenitors and not to
reduced apoptosis or impairment of their differentiating
ability.
Ring1B negatively regulates cyclin D2 and p16Ink4a. After
establishing the role of Ring1B in proliferation of hematopoi-
etic cells, we began to study the underlying mechanism(s) by
analyzing protein expression levels of known cell cycle regula-
tors. The rate of cell proliferation in mammalian cells is de-
termined mainly in the G1 phase of the cell cycle by the specific
activation of cyclin-dependent kinases, which are in turn neg-
atively regulated by two families of cyclin-dependent kinase
inhibitors (CKIs) (66). First, we compared total bone marrow
cell extracts from control MxCre-negative and in vivo deleted
Ring1B (MxCre positive) mice. Western blot analysis showed
increased levels of cyclin D2 (Fig. 4A) and also of the cell cycle
progression indicator cyclin A (see Fig. S4A in the supplemen-
tal material) in extracts from Ring1B-deficient cells. Also, lev-
els of the CKI p27 appeared slightly higher in mutant cells (see
Fig. S4 in the supplemental material). However, the most
prominent difference was observed for the levels of p16Ink4a,
another CKI which, while undetectable in extracts from non-
deleted cells, gave a strong signal in Ring1B-deficient cell ex-
tracts (Fig. 4A). No signals were detected for cdc6, a compo-
nent of the replication licensing machinery, the CKI p57, or
p19Arf in any of the extracts (see Fig. S4A in the supplemental
material).
Since the most immature cells (i.e., HSCs and progenitors)
represent only a minor contribution to total bone marrow cells,
we performed Western blot analysis on mutant and control
Lin cells (Fig. 3B). In contrast to whole bone marrow, the
expression pattern of cell cycle regulators in mutant Lin cells
showed an upregulation of proliferation activators cyclin D2
FIG. 3. Increased proliferation of Ring1B-deficient progenitors. (A to C) Proliferation and apoptosis of Lin cells isolated from Ring1Bf/f;
Cre-ERT2 bone marrow cells in the absence (Cre; top) or the presence (Cre; bottom) of 4-HT. (A) Solid plots correspond to cells labeled with
anti-BrdU antibodies. Overlaid empty plots correspond to cells labeled with isotype-matching FITC antibody to define the BrdU-negative
population. Proliferating, BrdU-positive cells (indicated by the bar) are shown as the mean  SD of two duplicate, independent experiments.
(B) CFDA-SE fluorescence content of mutant (4-HT; Cre) (bottom) or control (4-HT; Cre) (top) Lin cells, 18 h after immunoseparation
and fluorescent dye incubation. The empty histogram shows CFDA-SE cell content immediately after dye loading. (C) FITC-conjugated annexin
V labeling of propidium iodide-impermeable viable Lin cells cultured with (Cre; bottom) or without (Cre; top) 4-HT. The overlaid empty
histogram corresponds to cells treated under the same conditions but with no added annexin V. (D) Expression of lineage markers in cells from
mutant (light empty plots) and control (dark solid plots) myeloid colonies harvested at day 8. Gr-1, Mac-1, and CD41 markers stain mature cells
of the granulocytic, monocytic, and megakaryocytic lineages, respectively. Bars indicate positively labeled cells. (E) Mutant CMPs retain their
differentiation potential. Sorted mutant CMPs (Lin c-Kit CD34 FcRlo) cells were seeded into myeloid differentiation medium and individual
colonies appearing at day 7 (d 7)were labeled with antibodies to c-Kit, CD34, and FcR to determine MEP, CMP, and GMP content as
indicated in the legend of Fig. 2.
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(Fig. 4B, left), cyclin A, and cdc6 (see Fig. S4A in the supple-
mental material) with a concomitant absence of proliferation
inhibitors p16Ink4a (Fig. 4B, left), p27, and p57 (see Fig. S4A in
the supplemental material). However, the analysis of colonies
harvested from Lin cell methylcellulose cultures at day 8
showed a sustained upregulation of cyclin D2 together with a
dramatic increase of p16Ink4a levels in maturing Ring1B-defi-
cient cells only (Fig. 4B, middle panel), thus resembling the
expression pattern seen in unfractionated bone marrow cells.
A similar upregulation of p16Ink4a levels was observed in ex-
tracts from cultured mutant pre-B cells (Fig. 4B, right). Only
cyclin D3, which is needed for the expansion of pre-B cells
FIG. 4. Cell cycle regulator levels and proliferation rate are differentially affected by Ring1B along differentiation. (A and B) Representative
Western blots (3 to 15 independent experiments) from the indicated extracts. (A) Bone marrow extracts from mice in which the Ring1B locus has
been excised as a result of the expression of MxCre (/; Cre) and from Ring1Bf/f (f/f; Cre) mice. (B) Blots at left are extracts from Lin cells
immunomagnetically isolated from 4-HT-treated or untreated Ring1Bf/f; Cre-ERT2 bone marrow cells cultured for 48 h. Blots of extracts from
myeloid colonies harvested after culturing Lin cells for 8 days in methylcellulose medium without or with 4-HT are shown in the middle. At right
are blots of extracts from pooled pre-B-cell colonies grown after 8-day cultures of Ring1Bf/f and Ring1B-deficient bone marrow cells. Ctl, extracts
from mouse erythroleukemia cells; , with 4-HT treatment; , without 4-HT treatment. In panels A and B, Ponceau red-stained membranes were
used as a loading control. (C to F) Isolated Lin cells were cultured in suspension for the indicated times in differentiation medium containing
stem cell factor, IL-3, and IL-6 in the presence () or absence () of 4-HT. (C) Differential accumulation of mutant and control cells with time
in culture. Bars represent the average ratio of the percentage of mutant to control cells, considering the value of control cells as 1. (D) Switch in
the values of CFDA-SE fluorescence of cells in cultures in which the Ring1B locus has been excised as a result of 4-HT treatment (Cre) and in
untreated (nonexcised Ring1B; Cre) cultures at the indicated times. (E) FITC-conjugated annexin V labeling of propidium iodide-impermeable
viable cells present in day 6 cells cultured with (right) or without (left) 4-HT. Overlaid empty histogram corresponds to cells treated under the
same conditions but with no added annexin V. (F) Western blot analysis of cell extracts obtained from cells cultured in the presence () or the
absence () of 4-HT for the indicated times. Day 0 corresponds to extracts of Lin cells isolated from the bone marrow of Ring1Bf/f; Cre-ERT2
mice at the time of sacrifice. Controls and loading control are as described in panels A and B. (G) Ink4a promoter occupancy by Ring1B and Bmi1
in progenitors and maturing hematopoietic cells. At top is a schematic representation of the p16Ink4a gene locus shows exons and coding (filled)
sequences and the amplicon used for ChIP assays. Lin and Lin cell populations were immunomagnetically isolated from bone marrow and
chromatin analyzed using the indicated antibodies (bottom). Ex, exon; H3K27me3, trimethylated H3K27; IgG, immunoglobulin G; d, day.
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(13), was detected in these cells, and its expression was hardly
affected by the lack of Ring1B in either pre-B cells or myeloid
cells (see Fig. S4C in the supplemental material), suggesting
that the effect on cyclin D2 is specific. Modest increases in p27
and p57 levels were also observed in maturing mutant cells (see
Fig. S4B in the supplemental material). These data show that
Ring1B inactivation alters the expression pattern of cell cycle
regulators in differentiating cells and suggest that the resulting
populations of mature and immature cells are endowed with
reduced and enhanced proliferation rates, respectively.
We investigated these cell populations by using liquid cul-
tures of ex vivo Ring1B-ablated Lin cells under conditions
that recapitulate the differentiation events occurring in normal
myelopoiesis. Initially after treatment, the relative accumula-
tion of cells was faster in mutant (4-HT; Cre) than in
control (4-HT; Cre) cultures (Fig. 4C). However, by day 6
after treatment, this ratio was inverted, and Ring1B-expressing
cultures contained more cells than those of Ring1B-deficient
cells. Analysis of CFDA-SE fluorescence decay confirmed the
inversion of cell division rates between days 4 and 6 after 4-HT
(Fig. 4D) treatment. The lower accumulation of mutant cells
did not result from increased cell death, as determined by
annexin V staining (Fig. 4E). Instead, the late upregulation of
p16Ink4a, detected only by day 6 after treatment (Fig. 4F),
correlated with the switch in proliferation rate. This contrasted
with the prompt upregulation of the proliferation promoter
cyclin D2 in mutant cultures (Fig. 4F), which, in the absence of
the inhibitor p16Ink4a, would explain the enhanced prolifera-
tion observed before day 6. A possible explanation for the
differential regulation of p16Ink4a in immature versus mature
cells may be related to the decreasing levels of Bmi1 during
hematopoietic differentiation (26), which would ensure
p16Ink4a silencing in progenitors, even in the absence of
Ring1B. We tested this by analyzing promoter occupancy at
the Ink4a locus in ChIP assays and found that whereas Ring1B
was detected in both immature Lin and maturing Lin cells,
Bmi1 was seen associated predominantly in the immature com-
partment (Fig. 4G).
Collectively, these results show that through the balanced
expression of positive and negative cell cycle regulators,
Ring1B controls the expansion of differentiating hematopoi-
etic cells both by restricting proliferation of progenitors and by
contributing to their expansion during maturation.
Ink4a deficiency rescues only the expansion defects of
Ring1B-deficient hematopoietic cells. Given the correlation
seen between p16Ink4a upregulation and proliferation inhibi-
tion in maturing ex vivo Ring1B-deleted cells, the overall de-
crease of bone marrow cells associated with Ring1B inactiva-
tion could be explained by similar mechanisms. To test this
hypothesis, we crossed Ring1Bf/f; MxCre and Ring1Bf/f mice
with a mouse line carrying an Ink4a null mutation which does
not express either p16Ink4a or p19Arf (65). Bone marrow anal-
ysis after pIpC-induced Ring1B ablation showed that inactiva-
tion of the Ink4a locus abolished the differences in cellularities
of bone marrow and spleen observed in single Ring1B-deficient
cells (Fig. 5A). Furthermore, the severe reduction of pre-B-cell
colonies associated with Ring1B inactivation was not observed
in cultures of bone marrow cells that were also deficient in
Ink4a, which showed even a further increase in the number and
size of pre-B-cell CFU (Fig. 5B). In contrast, the increased
number of Ring1B-deficient myeloid CFU was not affected by
the lack of Ink4a (Fig. 5C), although the enlarged size of
double mutant colonies indicated that Ink4a products could act
by restricting the proliferative potential of maturing Ring1B-
deficient cells. Since p19Arf is not affected by Ring1B inactiva-
tion, the results confirm that the proliferative deficits of
Ring1B-deficient hematopoietic cells are due to the upregula-
tion of p16Ink4a in maturing cells.
Ring1B deficiency results in an accelerated onset of hema-
topoietic neoplasias in the absence of Ink4a. Mice with an
inactive Ink4a locus spontaneously develop and succumb to a
variety of tumors, mostly fibrosarcomas and lymphomas (62,
65). Remarkably, compound Ring1B; Ink4a mutant mice pre-
sented a quicker onset of fatal disease that lead to an acceler-
ation of the death rate, on average 11 weeks after Ring1B
ablation, as indicated in the survival plot shown in Fig. 6A.
Four out of the six compound mutant mice which could be
subjected to necropsy had developed splenomegalia and hepa-
tomegalia (Fig. 6B, left), resulting from infiltration by cells
which expressed the lymphoid marker Pax5 (Fig. 6E, right).
FIG. 5. Ink4a and Ring1B genetic interaction: Ink4a inactivation
rescues impaired proliferation of Ring1B-deficient (Ring1B/) matur-
ing cells. (A) Total or fractionated Lin bone marrow and total spleen
cell number from Ring1Bf/f; Ink4a/ (n 
 6) and Ring1B/; Ink4a/
(n 
 7) mice. (B) Pre-B-cell colonies from Ring1Bf/f; Ink4a/ and
Ring1B/; Ink4a/ bone marrow cells. Photographs correspond to
day 4 of culture and show the increased size and number of Ink4a
mutant colonies and, in particular, of double mutant cultures. Histo-
grams show pre-B-cell colony numbers at day 8 of culture. (C) Same
experiment as in panel B but in myeloid clonogenic methylcellulose
medium. Photographs were taken at day 8 of culture. Histograms
depict total myeloid colony numbers in day 8 cultures.
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The results show cooperation between the loss of function of a
tumor suppressor (Ink4a) and the inactivation of Ring1B,
which is in agreement with a role for Ring1B as a negative
regulator of cell proliferation.
DISCUSSION
Elucidating the mechanisms underlying tissue self-renewal is
important to understanding neoplastic processes. In this study,
we provide genetic evidence supporting a distinctive role for
the Polycomb protein Ring1B in the regulation of adult hema-
topoiesis. We find that Ring1B controls hematopoietic cell
proliferation by acting as not only a positive regulator, as other
PRC1 members, but also a negative regulator, depending on
the maturational stage of cell differentiation. Thus, while re-
stricting proliferation of early myeloid progenitors, Ring1B is
needed for the expansion of maturing, cell lineage-committed
precursors of both myeloid and lymphoid B-cell lineages. We
demonstrate that these effects are mediated, at least in part, via
downregulation of opposing cell cycle regulators, the G1 cyclin
D2 and its inhibitor p16Ink4a.
Dual roles of Ring1B in positive and negative regulation of
cell proliferation through downregulation of cell cycle inhibi-
tors and activators. The hematopoietic compartment is among
the tissues most affected by mutations in PcG genes, resulting
in smaller thymi and spleens and a hypocellular bone marrow
(36, 55). Inactivation of Ring1B results in a hematopoietic
phenotype milder than that of other PRC1 mutant mice but
equally consistent with a positive role in cell proliferation.
However, the enlargement of the size of the mutant progenitor
compartment indicates that Ring1B also acts as an antiprolif-
erative regulator. The accumulation of Ring1B-deficient imma-
ture cells seems to be due mostly to their hyperproliferative
phenotype rather than to reduced apoptosis or defective dif-
ferentiation. Thus, the antiproliferative activity of Ring1B con-
trasts with the most prominent role of other PRC1 subunits as
proliferation promoters, e.g., Bmi1. It also resembles that of
the PRC2 component Eed, whose inactivation antagonizes the
effects of a Bmi1 mutation (35). Moreover, the use of an ex
vivo inactivation model shows that these proliferative alter-
ations are, at least in part, the result of Ring1B cell-autono-
mous regulated events.
In agreement with a dual role for Ring1B in negative and
positive regulation of cell proliferation, we find that Ring1B
targets both cell cycle activators and inhibitors. Usually, the
activity of PcG proteins as promoters of cell proliferation is
associated to their role as repressors of the Ink4a locus (23).
We find that the inactivation of Ring1B also causes upregula-
tion of p16Ink4a but not of p19Arf, similarly to the previous
observation of Ink4a mRNA selective derepression in consti-
tutively Ring1B-deficient mouse embryos (72). In addition, our
analysis demonstrates that Ring1B regulates negatively the G1
cyclin D2 and the replication factor cdc6, two characteristic
promoters of cell proliferation.
Repression by PcG complexes usually refers to the mecha-
nisms dealing with maintenance of transcriptionally silent loci.
An example is the Ink4a/Arf locus, which is normally inactive in
proliferating cells. Association of PcG components, including
Ring1B, to genomic regions of Ink4a/Arf and its correlation
with the repressed state are considered indications of direct
transcriptional control (6, 21, 31). On the other hand, negative
regulation of transcriptionally active loci, such as cyclin D2 in
proliferating cells, appears as a novel scenario for Polycomb
repression. However, studies in Drosophila melanogaster show
that the Cyclin A gene, the product of which is needed for cell
cycle progression, is repressed by PRC1 subunits, Polycomb
and Polyhomeotic (42). Furthermore, Polycomb was found
associated to the Cyclin A locus, just as Ring1B and Bmi1
appear bound to regions of the Cyclin D2 gene in ES cells and
fibroblasts (5, 7). It is likely, then, that the presence of Poly-
comb complexes in the proximity of regulatory regions of ac-
tive loci (6, 8, 50) may serve a regulatory role for fine-tuning of
the transcriptional response. Regardless of the underlying
mechanism(s), the finding that Ring1B negatively regulates
cyclin D2 reinforces the notion that the role of PcG complexes
in cell proliferation includes the regulation of components of
the machinery involved in cell cycle progression.
Selective regulation of hematopoietic cell proliferation by
Ring1B and other PcG products. Normal hematopoiesis dis-
plays an orchestrated use of the cell cycle machinery compo-
nents in order to ensure the self-renewal and expansion activ-
ities associated with the various stages of cell differentiation of
hematopoietic lineages (53). These include proliferative re-
sponses as diverse as the high self-renewal capacity and low
proliferative rate of HSCs, the various proliferation rates of
their progeny along their maturation, or retrieval from active
proliferation of fully differentiated cells (58).
In our studies, Ring1B inactivation resulted in upregulation
of cyclin D2 in most hematopoietic cells analyzed, except for
B-cell precursors, whereas that of p16Ink4a was detected only in
maturing B and myeloid cells but not in progenitors, thus
providing an explanation for their altered proliferation rates.
FIG. 6. Loss of Ring1B accelerates the onset of tumors associated
to Ink4 inactivation. (A) Survival analysis of pIpC-injected Ring1Bf/f;
Ink4a/ (n 
 8; solid lines) and Ring1Bf/f; Ink4a/ MxCre (n 
 8;
dashed lines) mice. (B) Histochemical analysis of liver (left panel) and
spleen (right panel) of a mouse in which the Ring1B and Ink4a loci are
inactivated. Periportal (P) proliferation of tumor cells (arrows) with
sinusoidal colonization in midzone areas (arrowhead) and marked
distention of sinusoids (*) in the central vein (CV) area are shown. The
normal architecture of the spleen is effaced by a diffuse proliferation of
neoplastic cells. These tumor cells display positive immunostaining
with Pax-5 antibody. H/E, hematoxylin and eosin stain.
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Mutant myeloid progenitor hyperproliferation would result
from increased cyclin D2, in the absence of p16Ink4a, as it
occurs in Cyclin D2-transduced bone marrow cells (61). In
turn, progressive accumulation of p16Ink4a along differentia-
tion would abrogate the proliferative potential of the maturing
progeny, despite their high content of cyclin D2, thereby re-
sulting in a hypoplastic bone marrow. In this simple hypothesis,
inhibition, but not promotion, of proliferation caused by
Ring1B inactivation would be alleviated by loss of p16Ink4a.
Indeed, myeloid and B-cell precursors of mice bearing a coin-
cident loss of Ring1B and Ink4a proliferate efficiently, and the
reduced cellularity of Ring1B-deficient bone marrow is re-
stored in the compound mutant. Instead, the hyperprolifera-
tive phenotype elicited by Ring1B inactivation in myeloid pro-
genitors was not reversed by the absence of Ink4a. Altogether,
our data support a broad regulatory role for Ring1B in the
differentiation/expansion of adult hematopoietic cells by inte-
grating signals during amplification of immature progenitors
and during the expansion of their maturing progeny (Fig. 7).
The contrasting differences between hematopoietic alter-
ations associated with Ring1B ablation and those seen in mice
lacking some of their interacting partners in PRC1 com-
plex(es), i.e., Bmi1, Mel18, M33, and Mbt1 (1, 14, 71), are
likely a reflection of differential targeting in distinct cell types
by complexes that vary in composition or activity. For instance,
maintenance of repression of Ink4a/Arf in HSCs and early
progenitors occurs in the absence of Ring1B but not in the
absence of Bmi1 (48); another example is the p57 derepression
in Mbt1-null myeloid progenitors (2). Given the increasing
biochemical diversity of Ring1B-containing complexes (22, 47,
59), it appears that a definition of the expression pattern of
their subunits throughout the differentiation stages of the var-
ious lineages will be needed for a comprehensive understand-
ing of Polycomb complex function in hematopoiesis.
Ring1B-Ink4a interaction: implications for tumorigenesis.
The role of Ring1B as a proliferation promoter through re-
pression of inhibitors of cell proliferation is consistent with the
rescue of Ring1B-deficient bone marrow hypocellularity by
Ink4a/Arf inactivation. This observation is reminiscent of the
substantial restoration of the self-renewing capacity of HSCs
(48) and of thymocytes and splenocytes of Bmi1/ Ink4a/
Arf/ mice (9). Bmi1-mediated repression of Ink4a appears as
a causal agent of primed cell proliferation in tumors, and
protein expression analysis shows upregulation of Bmi1 in a
variety of tumor cells. Similarly, Ring1B protein expression is
increased in a variety of tumors (60), and its expression corre-
lates with poor prognosis in a subset of malignant human
cancers (24). However, the antiproliferative activity of Ring1B
may also play a role in the development of neoplastic pro-
cesses, as suggested by the decreased latency of tumor devel-
opment in mice whose bone marrow is doubly Ring1B and
Ink4a/Arf deficient compared to those lacking only Ink4a/Arf.
Since Ring1B inactivation does not lead to p19Arf upregulation,
the contribution of Ring1B in the absence of p16Ink4a to neo-
plastic events may lie in the presence of a population of pro-
genitors with enhanced self-renewal properties susceptible of
transformation (16, 32), thus cooperating with other genetic/
epigenetic lesions appearing during the onset and development
of tumors.
In conclusion, we have identified an antiproliferative role for
Ring1B in the expansion of progenitor cells, mediated by the
suppression of a positive regulator of the cell cycle machinery,
which may be important in the tight control of proliferation
occurring during adult hematopoiesis. It will be of interest to
investigate whether this role in cell turnover takes place also in
other self-renewing tissues.
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